Sign In
Buy DNA
$7.89
-0.110 (-1.38%)
At Close: Jun 12, 2026
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways
08:00am, Tuesday, 28'th Jan 2025
BOSTON--(BUSINESS WIRE)-- #ISO27001--Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.
Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC BOSTON , Jan. 23, 2025 /PRNewswire/ -- Gin
Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
07:26am, Tuesday, 21'st Jan 2025
FARGO, N.D.--(BUSINESS WIRE)--Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications.
Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON , Jan. 13, 2025 /PRNews
The Truveta collaboration will extend Regeneron Genetics Center's ® (RGC TM ) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteer
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
09:00am, Friday, 10'th Jan 2025
- Signals Start of New Commercialization Phase for LineaRx Subsidiary - - Company Negotiating GMP Supply Agreement - - Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE
Rapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and Genomics
11:38am, Thursday, 09'th Jan 2025
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Enzymatic DNA Synthesis Market by Service, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. The gl
KBRA Assigns Preliminary Ratings to Freddie Mac's STACR 2025-DNA1
10:29am, Thursday, 09'th Jan 2025
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 24 classes from Freddie Mac Structured Agency Credit Risk (STACR®) REMIC 2025-DNA1 Notes, Freddie Mac STACR REMIC
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Thursday, 09'th Jan 2025
BOSTON , Jan. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, i
STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announ
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
09:00am, Wednesday, 18'th Dec 2024
- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies - STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA S
- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership - - Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025 - - Webcast and Conference Call
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy
01:01pm, Tuesday, 17'th Dec 2024
Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders BOSTON , Dec. 17, 2024 /PRNewswire/ -- Ginkgo Biowo
STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today anno
